Liquidia Corp investor relations material
Listen to the latest call from Liquidia Corp
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina. It has subsidiary offices throughout North America and Europe.
Ticker
LQDACountry
USAbout
IR-page